AbbVie to Acquire Gilgamesh’s Bretisilocin, Boosting Psychiatry Pipeline for Depression
AbbVie and Gilgamesh Pharmaceuticals have entered into a definitive agreement under which AbbVie will acquire Gilgamesh’s lead investigational candidate, bretisilocin, a next-generation…
Read More...
Read More...
